Log in

InMed Pharmaceuticals Stock Price, News & Analysis (TSE:IN)

-0.02 (-7.41 %)
(As of 10/13/2019 04:00 PM ET)
Today's Range
Now: C$0.25
50-Day Range
MA: C$0.32
52-Week Range
Now: C$0.25
Volume76,500 shs
Average Volume204,185 shs
Market CapitalizationC$43.07 million
P/E RatioN/A
Dividend YieldN/A
InMed Pharmaceuticals Inc., a pre-clinical stage biopharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-750, a topical cannabinoid product candidate to treat epidermolysis bullosa. The company is also involved in developing INM-085, a cannabinoid-based topical therapy for glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of drugs for the treatment of various diseases, including dermatology, ocular, pain, inflammation, cancer, and other disease areas. It has an agreement with Pharmaseed Ltd to develop a final formulation for INM-750; and work on IND-enabling pharmacology and toxicology studies. The company also has research agreement with the National Research Council of Canada in for biofermentation development and scale-up processes for cannabinoid biosynthesis in E.coli. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic



Sales & Book Value

Annual SalesN/A
Cash FlowC$0.10 per share
Book ValueC$0.11 per share



Market CapC$43.07 million
Next Earnings Date11/11/2019 (Estimated)
OptionableNot Optionable

Receive IN News and Ratings via Email

Sign-up to receive the latest news and ratings for IN and its competitors with MarketBeat's FREE daily newsletter.

InMed Pharmaceuticals (TSE:IN) Frequently Asked Questions

What is InMed Pharmaceuticals' stock symbol?

InMed Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "IN."

How were InMed Pharmaceuticals' earnings last quarter?

InMed Pharmaceuticals Inc (TSE:IN) posted its earnings results on Thursday, September, 19th. The company reported ($0.02) earnings per share for the quarter, meeting the Zacks' consensus estimate of ($0.02). View InMed Pharmaceuticals' Earnings History.

When is InMed Pharmaceuticals' next earnings date?

InMed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November 11th 2019. View Earnings Estimates for InMed Pharmaceuticals.

What is the consensus analysts' recommendation for InMed Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InMed Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for InMed Pharmaceuticals.

Has InMed Pharmaceuticals been receiving favorable news coverage?

Media headlines about IN stock have trended negative on Sunday, according to InfoTrie Sentiment. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. InMed Pharmaceuticals earned a news sentiment score of -2.6 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for InMed Pharmaceuticals.

Who are some of InMed Pharmaceuticals' key competitors?

What other stocks do shareholders of InMed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InMed Pharmaceuticals investors own include TENCENT HOLDING/ADR (TCEHY), Auscann Group (AC8), Namaste Technologies (N), OrganiGram (OGI), Baidu (BIDU), Insys Therapeutics (INSY), Nutanix (NTNX), NVIDIA (NVDA), Trade Desk (TTD) and TAKE-TWO INTERACTIVE SOFTWARE (TTWO).

Who are InMed Pharmaceuticals' key executives?

InMed Pharmaceuticals' management team includes the folowing people:
  • Mr. Eric A. Adams, Pres, CEO & Director (Age 56)
  • Mr. Jeffrey M. Charpentier, CFO & Corp. Sec.
  • Ms. Alexandra D. J. Mancini, Sr. VP of Clinical & Regulatory Affairs
  • Mr. Joshua Blacher, Chief Bus. Officer (Age 46)
  • Dr. Eric C. Hsu, Sr. VP of Preclinical R&D

How do I buy shares of InMed Pharmaceuticals?

Shares of IN and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is InMed Pharmaceuticals' stock price today?

One share of IN stock can currently be purchased for approximately C$0.25.

How big of a company is InMed Pharmaceuticals?

InMed Pharmaceuticals has a market capitalization of C$43.07 million. InMed Pharmaceuticals employs 4 workers across the globe.View Additional Information About InMed Pharmaceuticals.

What is InMed Pharmaceuticals' official website?

The official website for InMed Pharmaceuticals is http://www.inmedpharma.com/.

How can I contact InMed Pharmaceuticals?

The company can be reached via phone at 604-669-7207.

MarketBeat Community Rating for InMed Pharmaceuticals (TSE IN)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  3 (Vote Outperform)
Underperform Votes:  1 (Vote Underperform)
Total Votes:  4
MarketBeat's community ratings are surveys of what our community members think about InMed Pharmaceuticals and other stocks. Vote "Outperform" if you believe IN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/13/2019 by MarketBeat.com Staff

Featured Article: Retained Earnings

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel